ATAI Life Sciences, a biotechnology company, completed a $12m investment in IntelGenx Technologies, a pharmaceutical films company. "We would again like to thank our shareholders for their support of our transformative strategic partnership with atai. In addition to positioning IntelGenx as a leader within the novel therapeutics field of psychedelics, atai’s investment provides us with the requisite financial resources to continue to advance our portfolio of other pharmaceutical film product candidates towards commercialization," Horst G. Zerbe, IntelGenx CEO.